Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Eledon Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Eledon Pharmaceuticals, Inc.

ELDN

Eledon Pharmaceuticals, Inc.

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals is a biotech company focused on developing immunology-based therapies targeting the CD40 Ligand pathway. Its lead candidate, tegoprubart, is an anti-CD40L antibody designed to prevent organ transplant rejection, treat autoimmune diseases, and address neurodegenerative conditions like ALS. The company advances its products through clinical trials, leveraging proprietary IP, and collaborates with research institutions to improve transplant outcomes and neuroinflammation management.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Eledon Pharmaceuticals, Inc.

1
1
Eledon Pharmaceuticals, Inc. Eledon Pharmaceuticals Reports $39M Net Loss in Q1 2026, Focuses on Tegoprubart Development

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Eledon Pharmaceuticals, Inc. Eledon Pharmaceuticals Reports $45.6 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Eledon Pharmaceuticals, Inc. Eledon Pharmaceuticals Reports $17.5 Million Net Loss in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Eledon Pharmaceuticals, Inc. Eledon Pharmaceuticals Reports $17.7 Million Net Loss, Focuses on Tegoprubart Development

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Eledon Pharmaceuticals, Inc. Eledon Pharmaceuticals Reports $6.5 Million Net Loss in Q1 2025, Focuses on Tegoprubart Development

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Eledon Pharmaceuticals, Inc. Eledon Pharmaceuticals Reports Improved Financial Performance and Focus on Kidney Transplantation Programs

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Eledon Pharmaceuticals, Inc. Eledon Pharmaceuticals Reports Significant Financial Improvements, Net Income Turnaround in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments